Drug Type Recombinant polypeptide |
Synonyms Cagrilintide/Semaglutide |
Target |
Mechanism AMYR agonists(Amylin receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 3 | CZ | 27 Sep 2023 | |
Diabetes Mellitus, Type 2 | Phase 3 | SI | 27 Sep 2023 | |
Diabetes Mellitus, Type 2 | Phase 3 | HR | 27 Sep 2023 | |
Diabetes Mellitus, Type 2 | Phase 3 | FI | 27 Sep 2023 | |
Diabetes Mellitus, Type 2 | Phase 3 | MX | 27 Sep 2023 | |
Diabetes Mellitus, Type 2 | Phase 3 | BG | 27 Sep 2023 | |
Diabetes Mellitus, Type 2 | Phase 3 | CO | 27 Sep 2023 | |
Diabetes Mellitus, Type 2 | Phase 3 | DK | 27 Sep 2023 | |
Obesity | Phase 3 | CN | 15 Aug 2023 | |
Obesity | Phase 3 | CN | 15 Aug 2023 |
Not Applicable | - | - | zkyedkxuco(qndulbbcoz) = ordfqzbfnw vrrufgpohd (yxxgdrtmzj ) View more | Positive | 03 Oct 2023 | ||
zkyedkxuco(qndulbbcoz) = flhcbmarqj vrrufgpohd (yxxgdrtmzj ) | |||||||
Not Applicable | - | - | Vehicle control | eoslfrnurn(siaoofeekw) = whzmohelzn lfdgeaqwqx (torkreeguf ) View more | - | 21 Nov 2022 | |
eoslfrnurn(siaoofeekw) = cybimzpddm lfdgeaqwqx (torkreeguf ) View more |